<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01242891</url>
  </required_header>
  <id_info>
    <org_study_id>EXCOR® Continued Access</org_study_id>
    <nct_id>NCT01242891</nct_id>
  </id_info>
  <brief_title>Assess Safety and Probable Benefit of the EXCOR® Pediatric Ventricular Assist Device Under a Continued Access Protocol</brief_title>
  <acronym>CAP</acronym>
  <official_title>A Prospective, Multi-center, Single Arm Study to Assess the Safety and Probable Benefit of the Berlin Heart EXCOR® Pediatric Ventricular Assist Device (EXCOR® Pediatric)Under a Continued Access Protocol.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Berlin Heart, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Berlin Heart, Inc</source>
  <brief_summary>
    <textblock>
      The main purpose of this protocol is to provide a mechanism for continued access for patients&#xD;
      that would have been enrolled into the primary cohorts of the IDE study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The data collection and protocols for this study remain consistent with the main IDE study&#xD;
      for the EXCOR® Pediatric Ventricular Assist Device. This protocol was closed at the same time&#xD;
      as the main IDE study due to FDA approval (December 16, 2011).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathies</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EXCOR® Pediatric Ventricular Assist Device</intervention_name>
    <description>Extracorporeal Ventricular Assist Device</description>
    <other_name>Berlin Heart</other_name>
    <other_name>EXCOR®</other_name>
    <other_name>EXCOR® Pediatric</other_name>
    <other_name>EXCOR® Pediatric VAD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Severe New York Heart Association (NYHA) Functional Class IV (or Ross Functional Class IV&#xD;
        for patients &lt;= 6 years) heart failure refractory to optimal medical therapy, and has met&#xD;
        at least one of the following criteria:&#xD;
&#xD;
          -  INTERMACS profile status 1 or 1A, i.e. critical cardiogenic shock (low BP unresponsive&#xD;
             to support), compromised end organ perfusion, &lt; 24 hour survival without mechanical&#xD;
             support; may be due to Ventricular Tachycardia (VT)/Ventricular Fibrillation (VF) (1A)&#xD;
             OR&#xD;
&#xD;
          -  INTERMACS profile status or 2A (i.e progressive decline): not in imminent danger, but&#xD;
             worsening despite optimal inotropic therapy; may be due to VT/VF (2A) AND at least one&#xD;
             of the following criteria: Decline in renal functions, Decline in nutritional status,&#xD;
             Decline in mobility/ambulation&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Support with extra-corporeal membrane oxygenation (ECMO) or other mechanical&#xD;
             circulatory support device OR&#xD;
&#xD;
          -  Unable to separate from cardiopulmonary bypass&#xD;
&#xD;
               -  Listed (UNOS status 1A or equivalent) for cardiac transplantation&#xD;
&#xD;
               -  Two-ventricle circulation, including cardiomypathy, repaired structural heart&#xD;
                  disease or acquired heart disease&#xD;
&#xD;
               -  Age 0 to 16 years&#xD;
&#xD;
               -  Weight &gt;= 3 kg and &lt;= 60 kg&#xD;
&#xD;
               -  Legal guardian (and patient if age-appropriate) understands the nature of the&#xD;
                  procedure, is willing to comply with associated follow-up evaluations, and&#xD;
                  provide written informed consent and assent prior to the procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Support on ECMO for &gt;= 10 days&#xD;
&#xD;
          -  Cardiopulmonary resuscitation (CPR) duration &gt;= 30 minutes within 48 hours of&#xD;
             implantation&#xD;
&#xD;
          -  Body weight &lt; 3.0 kg or Body Surface Area &gt; 1.5 m2&#xD;
&#xD;
          -  Presence of mechanical aortic valve&#xD;
&#xD;
          -  Unfavorable or technically-challenging cardiac anatomy including single ventricle&#xD;
             lesions, complex heterotaxy, and restrictive cardiomyopathy&#xD;
&#xD;
          -  Evidence of intrinsic hepatic disease&#xD;
&#xD;
          -  Evidence of intrinsic renal disease&#xD;
&#xD;
          -  Evidence of intrinsic pulmonary disease&#xD;
&#xD;
          -  Hemodialysis or peritoneal dialysis (not including dialysis or continuous veno-venous&#xD;
             hemofiltration (CVVH) for fluid removal)&#xD;
&#xD;
          -  Moderate or severe aortic and/or pulmonic valve insufficiency&#xD;
&#xD;
          -  Apical VSD or other compromise that is technically challenging to repair at implant&#xD;
&#xD;
          -  Documented heparin induced thrombocytopenia (HIT)&#xD;
&#xD;
          -  Documented coagulopathy&#xD;
&#xD;
          -  Hematologic disorder&#xD;
&#xD;
          -  Active Infection within 48 hours of implant (positive blood culture or White Blood&#xD;
             Cell count &gt;15,000 and fever &gt; 38 degrees C)&#xD;
&#xD;
          -  Documented Human immunodeficiency virus (HIV) infection or acquired immunodeficiency&#xD;
             syndrome (AIDS)&#xD;
&#xD;
          -  Evidence of recent life-limiting malignant disease&#xD;
&#xD;
          -  Stroke within 30 days prior to enrollment&#xD;
&#xD;
          -  Psychiatric or behavioral disease&#xD;
&#xD;
          -  Currently participating in another IDE or IND trial&#xD;
&#xD;
          -  Patient is pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>16 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>All Previous IDE Sites</last_name>
    <role>Principal Investigator</role>
    <affiliation>See IDE Clinical Trials Listing for IDE Study</affiliation>
  </overall_official>
  <link>
    <url>http://www.berlinheart.com</url>
    <description>Berlin Heart Inc</description>
  </link>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>November 16, 2010</study_first_submitted>
  <study_first_submitted_qc>November 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2010</study_first_posted>
  <last_update_submitted>March 2, 2012</last_update_submitted>
  <last_update_submitted_qc>March 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventricular Assist Device</keyword>
  <keyword>Pediatric Ventricular Assist Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

